NANO Nanobiotix S.A.

28.45USD25.94 EUR · EPA+7.63%Mkt Cap: 1.45B USDP/E: —

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …

Institutional holders10 on file

Key Statistics

Company
Market Cap1.45B USD
Enterprise Value1.44B USD
Revenue (TTM)12.62M USD
Gross Profit12.62M USD
Net Income (TTM)-26.28M USD
Revenue/Share0.26 USD
Last Price28.45 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees98
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0011341205
Valuation
P/E (Trailing)—
P/E (Forward)Infinity
PEG—
EV/EBITDA-44.10
EV/Revenue114.16
P/S114.86
P/B-39.48
EPS (TTM)-1.20 USD
EPS (Forward)0.00 USD
52W Range
18.1230% of range52.27
52W High52.27 USD
52W Low18.12 USD
Profitability
Gross Margin100.00%
Oper. Margin-257.43%
EBITDA Margin-258.87%
Profit Margin-80.83%
ROE28.36%
ROA-35.36%
ROIC—
ROCE-105.51%
Growth
Revenue Growth-79.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.66M USD
CapEx (TTM)598.85K USD
FCF Margin-284.91%
FCF Yield-2.48%
Net Debt-4.69M USD
Net Debt/EBITDA0.14
Net Debt/FCF—
Balance Sheet
Debt/Equity-1.13
Current Ratio1.44
Quick Ratio1.40
Book Value/Sh-0.72 USD
Cash/Share2.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)57.26 USD
Upside (mean)+101.2%
Target Range43.87 USD – 65.82 USD
43.87+101.2% to mean65.82
# Analysts5
Ownership
Shares Out.50.95M
Float35.15M
Insiders15.44%
Institutions31.11%
Technical
SMA 5028.84 (-1.3%)
SMA 20032.82 (-13.3%)
Beta0.54
S&P 52W Chg12.00%
Avg Vol (30d)189.93K
Avg Vol (10d)108.38K
Technical Indicators
RSI (14)47.9
MACD0.0114
MACD Signal0.3244
MACD Hist.-0.3130
BB Upper34.31 USD
BB Middle30.14 USD
BB Lower25.98 USD
BB Width27.66%
ATR (14)2.090 USD
Vol Ratio (20d)0.46x

About Nanobiotix (EPA: NANO)

›

Nanobiotix (EPA: NANO) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 98 employees.

The shares were at 25.94 EUR on 19 November 2026, up 42.5% over 52 weeks. Its 52-week range is 16.52 EUR to 47.66 EUR: the price is 45.6% below the high and 57.0% above the low.

Its market capitalisation is 1.32B EUR.

Nanobiotix reports return on equity of 28.4%, an operating margin of -257.4% and revenue down 79.2% year over year.

It holds more cash than debt, a net cash position of 4.28M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock; their mean price target of 52.20 EUR is 101.2% above the current price. The next earnings report is expected on 30 March 2027.